The company reported Q2 2026 revenue of $3.73 billion compared to $3.53 billion in the year-ago period, beating Wall Street's consensus estimate of $3.71 billion.

The partners are also working together to validate the company's molecular testing technologies in various settings.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.

NEW YORK – As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. Staffing is a problem for the ...

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.

The company had previously been notified that its stock did not meet the Nasdaq's minimum bid price requirement.

Last week, readers were most interested in a story about Tempus' offer to buy cancer diagnostic firm Personalis for $1.5 billion.

NEW YORK – Quest Diagnostics raised its full-year 2026 revenue and EPS guidance on Thursday as the company saw solid Q2 growth across its business. The firm said it now expects full-year net revenue ...